<DOC>
	<DOC>NCT02712034</DOC>
	<brief_summary>The primary aim of this study is to measure and explain the impact on long-term opioid use when medication-assisted treatment (MAT) is bundled with an evidence-based mobile-health system (A-CHESS).</brief_summary>
	<brief_title>Impact on Opioid Use of Bundling Medication-assisted Treatment With mHealth</brief_title>
	<detailed_description />
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>1. are 18+ years old; 2. meet criteria for opioid use disorders of at least moderate severity (4 or 5 DSMV criteria); 3. Are currently taking medicationassisted treatment (MAT) as part of their standard clinical care; 4. have no acute medical problem requiring immediate inpatient treatment; 5. have no history of psychotic disorders, though those with other comorbid psychopathology (mood disorders, anxiety, other substance use disorders) will be eligible; 6. are willing to participate in a randomized clinical trial; 7. provide the name, verified telephone number, and address of at least 2 contacts willing to help locate the patient, if necessary, during followup; 8. are able to read and write in English; 9. are not pregnant; 10. are willing to share healthrelated data with primary care clinicians; and 11. are, at study intake, abstinent from opioids for at least 1 week and no longer than 2 months, except for medications used to treat the disorder (e.g., methadone).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Medication-assisted treatment (MAT)</keyword>
	<keyword>Buprenorphine</keyword>
	<keyword>Methadone</keyword>
	<keyword>Naltrexone</keyword>
</DOC>